-       Report 
- November 2024
-  240 Pages 
- Global 
   From       €1709EUR$1,920USD£1,504GBP 
      €2136EUR$2,400USD£1,880GBP 
          -       Report 
- September 2025
-  313 Pages 
- Global 
   From       €4405EUR$4,950USD£3,877GBP 
          -       Report 
- May 2025
-  170 Pages 
- Global 
   From       €4138EUR$4,650USD£3,642GBP 
          -       Report 
- April 2025
-  162 Pages 
- Global 
   From       €4138EUR$4,650USD£3,642GBP 
            -       Report 
- September 2025
-  180 Pages 
- Global 
   From       €5295EUR$5,950USD£4,661GBP 
           -       Report 
- June 2025
-  170 Pages 
- Global 
   From       €5295EUR$5,950USD£4,661GBP 
          -       Report 
- March 2025
-  225 Pages 
- Global 
   From       €5295EUR$5,950USD£4,661GBP 
          -       Report 
- August 2025
- Global 
   From       €4405EUR$4,950USD£3,877GBP 
            -       Report 
- October 2025
-  194 Pages 
- Global 
   From       €3155EUR$3,545USD£2,777GBP 
      €3505EUR$3,939USD£3,085GBP 
            -       Report 
- October 2025
-  197 Pages 
- Global 
   From       €3155EUR$3,545USD£2,777GBP 
      €3505EUR$3,939USD£3,085GBP 
            -       Report 
- October 2025
-  197 Pages 
- Global 
   From       €3155EUR$3,545USD£2,777GBP 
      €3505EUR$3,939USD£3,085GBP 
            -       Report 
- October 2025
-  198 Pages 
- Global 
   From       €3155EUR$3,545USD£2,777GBP 
      €3505EUR$3,939USD£3,085GBP 
            -       Report 
- October 2025
-  182 Pages 
- Global 
   From       €3155EUR$3,545USD£2,777GBP 
      €3505EUR$3,939USD£3,085GBP 
            -       Report 
- October 2025
-  196 Pages 
- Global 
   From       €3155EUR$3,545USD£2,777GBP 
      €3505EUR$3,939USD£3,085GBP 
            -       Report 
- October 2025
-  190 Pages 
- Global 
   From       €3155EUR$3,545USD£2,777GBP 
      €3505EUR$3,939USD£3,085GBP 
            -       Report 
- October 2025
-  191 Pages 
- Global 
   From       €3155EUR$3,545USD£2,777GBP 
      €3505EUR$3,939USD£3,085GBP 
            -       Report 
- October 2025
-  183 Pages 
- Global 
   From       €3155EUR$3,545USD£2,777GBP 
      €3505EUR$3,939USD£3,085GBP 
            -       Report 
- October 2025
-  184 Pages 
- Global 
   From       €3155EUR$3,545USD£2,777GBP 
      €3505EUR$3,939USD£3,085GBP 
            -       Report 
- October 2025
-  190 Pages 
- Global 
   From       €3155EUR$3,545USD£2,777GBP 
      €3505EUR$3,939USD£3,085GBP 
            -       Report 
- October 2025
-  191 Pages 
- Global 
   From       €3155EUR$3,545USD£2,777GBP 
      €3505EUR$3,939USD£3,085GBP 
       
      Bispecific antibodies are a type of biotechnology that are used to target two different antigens simultaneously. They are engineered to bind to two different epitopes on the same or different antigens, allowing them to act as a bridge between two different cells or molecules. Bispecific antibodies have been used in a variety of therapeutic applications, including cancer immunotherapy, autoimmune diseases, and infectious diseases.
Bispecific antibodies have the potential to improve the efficacy of    existing treatments and to develop new treatments for diseases that have not yet been addressed. They can also be used to target multiple antigens at once, allowing for more efficient and effective treatments.
The bispecific antibodies market is expected to grow significantly in the coming years due to the increasing demand for targeted therapies and the development of new technologies. Companies in the market include AbbVie, Amgen, AstraZeneca, Biogen, Boehringer Ingelheim, Celgene, Genentech, GlaxoSmithKline, Merck, Novartis, and Pfizer. Show Less   Read more